Genomic Cancer Panel and Profiling Market Trends Influenced by Next-Generation Sequencing and PCR Technologies

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Genomic Cancer Panel and Profiling Market - (By Tissue Testing (Solid Tissue Testing, Liquid Tissue Testing), By Cancer Panel Type (Single-Gene Panel, Multi-Gene Panel), By Cancer Type (Lung Cancer, Breast Cancer, Colon Cancer, Prostate Cancer, Other Cancers), By Application (Clinical, Research), By Technology (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescence In-Situ Hybridization (FISH), Immunohistochemistry (IHC), Others), By End User (Hospitals, Clinical and Diagnostic Laboratories, Research and Academic Institutes)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031."

According to the latest research by InsightAce Analytic, the Global Genomic Cancer Panel and Profiling Market is valued at US$ 9.29 Bn in 2022, and it is expected to reach US$ 18.69 Bn by 2031, with a CAGR of 8.38% during the forecast period of 2023-2031.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2292

Genomic cancer panels and profiling entail the detailed examination of tumor DNA to identify genetic mutations and alterations associated with cancer development and progression. This comprehensive genomic information is critical for enabling early cancer detection and informing the design of personalized treatment strategies. The market for genomic cancer panels is expanding, driven by their pivotal role in advancing precision oncology.

Increasing global prevalence of hereditary cancers has further elevated the demand for these diagnostic solutions, given their high accuracy in detecting inherited genetic abnormalities linked to malignancies. However, market growth is constrained by several factors, including inadequate storage infrastructure, a clinical preference for immunotherapy over genetic testing in certain treatment pathways, and limited access to high-quality biospecimens, all of which may hinder broader adoption and industry expansion.

List of Prominent Players in the Genomic Cancer Panel and Profiling Market:
• Agilent Technologies, Inc.
• ARUP Laboratories
• Burning Rock DX
• Caris Life Sciences
• Thermo Fisher Scientific, Inc.
• Danaher Corporation (Integrated DNA Technologies, Inc.)
• Exact Sciences Corporation
• F. Hoffmann-La Roche Ltd
• Fulgent Genetics
• Genecast Biotechnology Co., Ltd
• Illumina, Inc.
• Invitae Corporation
• QIAGEN N.V.
• NeoGenomics, Inc.
• Sysmex Corporation
• HTG Molecular Diagnostics, Inc.
• Predictive Oncology, Inc.
• NanoString Technologies, Inc.
• Guardant Health, Inc.
• Foundation Medicine
• Genscript Biotech Corporation
• Tempus Labs
• Hologic, Inc.
• Others

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-04

Market Dynamics
Drivers:
The expansion of the genomic cancer panel and profiling market is primarily driven by significant advancements in oncology biomarker research and molecular diagnostics. The discovery of novel therapeutic targets and the development of corresponding pharmacological interventions have been instrumental in fostering market growth. Biomarkers play a pivotal role in clinical research, supporting accurate disease diagnosis, the design of personalized treatment regimens, and the identification of surrogate endpoints.

Recent efforts to enhance biomarker sensitivity and specificity through extensive scientific and clinical investigations across multiple therapeutic areas are further reinforcing their utility. Given their proven effectiveness in enabling precise cancer detection, the application of biomarkers in cancer and tumor profiling is expected to grow substantially in the coming years.

Challenges:
The market faces several constraints that could impede its growth. High costs associated with biomarker discovery, production, and clinical validation remain a significant barrier, as the transition from research to clinical application involves rigorous, time-intensive processes. Additionally, the elevated price of genomic profiling tests limits accessibility for a broad segment of patients, restricting widespread adoption.

A shortage of skilled personnel further complicates implementation, particularly in developing regions lacking standardized testing protocols. The COVID-19 pandemic exacerbated these challenges by delaying routine cancer diagnostics and reducing cancer detection rates, partly due to temporary decreases in false-positive results, thereby impacting market performance.

Regional Trends:
North America is anticipated to maintain a dominant position in the global genomic cancer panel and profiling market, driven by substantial R&D investments, a high incidence of cancer cases, and advanced healthcare infrastructure that emphasizes precision medicine. Europe also represents a significant market, supported by technological innovation, economic stability, and rising demand for targeted cancer therapies. Key growth drivers in the region include improvements in healthcare delivery systems, expanded applications of genomic profiling across diverse cancer types, and accelerated initiatives in drug discovery and clinical development.

Recent Developments:
• In April 2023, Agilent Technologies Inc. has introduced the Agilent SureSelect Cancer CGP Assay, specifically developed for the analysis of genetic variations in various types of solid tumors. The design of the pan-cancer test was formulated using a Next-Generation Sequencing (NGS) panel. This panel consisted of 679 genes that were carefully selected from prominent cancer databases worldwide. The development of this panel was done in collaboration with recognized clinical cancer researchers. The test workflow demonstrated high efficiency, allowing for automation and adaptability, hence increasing the accessibility of tumor molecular profiling to a wide range of clinical researchers.
• In March 2022, Illumina, Inc. has introduced TruSightTM Oncology (TSO) Comprehensive (EU), a novel assay that examines several tumor genes and biomarkers to uncover the precise molecular characteristics of a patient's cancer. The in vitro diagnostic (IVD) kit was initially introduced in Europe, serving as a valuable tool for guiding precision medicine choices for cancer patients throughout the continent.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/2292

Segmentation of Genomic Cancer Panel and Profiling Market-
By Tissue Testing-
• Solid Tissue Testing
• Liquid Tissue Testing
By Cancer Panel Type
• Single-Gene Panel
• Multi-Gene Panel
By Cancer Type-
• Lung Cancer
• Breast Cancer
• Colon Cancer
• Prostate Cancer
• Other Cancers
By Application-
• Clinical
• Research
By Technology-
• Next-Generation Sequencing (NGS)
• Polymerase Chain Reaction (PCR)
• Fluorescence In-Situ Hybridization (FISH)
• Immunohistochemistry (IHC)
• Others
By End User-
• Hospitals
• Clinical and Diagnostic Laboratories
• Research and Academic Institutes
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of the Middle East and Africa

Read Overview Report- https://www.insightaceanalytic.com/report/genomic-cancer-panel-and-profiling-market/2292

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: https://www.insightaceanalytic.com/
Tel : +1 607 400-7072
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.